Project Description

Join Cancer Specialist Dr. Joel Epstein to Learn How a New Class of Drugs Is Being Developed to Prevent the Painful and Dose-Limiting Effects of Cancer Therapies

Date & Time:

June 10, 11:00 AM ET / 8:00 AM PT
Webinar: Details provided upon RSVP approval

About the Event:

As a cancer specialist at Cedars-Sinai in L.A., Dr. Joel Epstein has seen the devastating effects mucositis has on patients. Currently they try to mitigate the pain with opioids and prevent infection with antibiotics, but that provides very little relief, and oncologists often have to cut cancer treatments short.

Upon seeing the latest trial results for Tosk’s TK-90, Dr. Epstein said, “I need something like this to keep my patients on their treatment plans.”

Dr. Epstein is just one of our esteemed panelists who will shed light on the challenges side effect present to cancer treatment. Space is limited so please sign up for this important webinar today.



Ian Ferrier

Dr. Ferrier has held senior level responsibility for product development and commercialization at AstraZeneca and Solvay and, the over past thirty years, has led BDF, and more recently its sister company Sibelius LLC to leadership in their fields. Dr. Ferrier continues to serve on the boards of private and public companies. He received his medical and pharmacology degrees from the University of Edinburgh.


Dr. Joel Epstein

Dr. Epstein is Medical Director of the Cancer Dentistry Program at Cedars-Sinai Medical Center in Los Angeles. He graduated from Dentistry from the University of Saskatchewan, received a certificate in Oral Medicine and Masters’ of Science Degree in Dentistry from the University of Washington, is a Fellow of the College of Dental Surgeons of Canada in Oral Medicine/Oral Pathology, and a Fellow of the Royal College of Surgeons of Edinburgh.

Dr. Giuseppe Pizzorno

Dr. Pizzorno is Professor, Associate Dean for Research, and Chief Research Officer at the University of Tennessee Health Science Center College of Medicine and the Erlanger Health System. Previously, he was Vice President of Research Operations and Deputy Director of the Nevada Cancer Center where he led translational cancer research activities.

Dr. Bill Garland

Dr. Garland is VP R&D at Tosk Inc. His experience spans all aspects of drug development from discovery through regulatory approval. Previously, Dr. Garland served as Chief Executive Officer and Director of AngioGenex, and held senior development and scientific affairs positions at Lpath Therapeutics, Atairgin Technologies, Centaur Pharmaceuticals, and Hoffmann-La Roche where his last position was Senior Director and US Head of International Project Management. Dr. Garland received a BS in chemistry from the University of San Francisco, a PhD in medicinal chemistry from the University of Washington, and has authored or co-authored over 100 scientific publications.

Please join this important panel discussion to hear how reducing the toxicity of cancer treatment results in better care.

Share this Event

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.